Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).

被引：3

作者：

Lacy, Jill

Portales, Fabienne

Hammel, Pascal

Cid, Roberto A. Pazo

Mozo, Jose Luis Manzano

Kim, Edward Jae-hoon

Dowden, Scot D.

Borg, Christophe

Sastre, Javier

Bathini, Venu Gopal

Terrebonne, Eric

Lopez-Trabada, Daniel

Rivera, Fernando

Asselah, Jamil

Damiani, Azzurra

Hwang, Jimmy J.

Ong, Teng Jin

Nydam, Thom

Li, Jack Shiansong

Philip, Philip Agop

机构：

[1] Yale Canc Ctr, New Haven, CT USA

[2] Inst Reg Canc Montpellier ICM, Montpellier, France

[3] Hop Beaujon, Clichy, France

[4] Hosp Miguel Servet, Zaragoza, Spain

[5] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[6] UC Davis Comprehens Canc Ctr, Sacramento, CA USA

[7] Tom Baker Canc Clin, Calgary, AB, Canada

[8] Ctr Hosp Belfort Montbeliard, Montbeliard, France

[9] Hosp Clin San Carlos, Madrid, Spain

[10] Univ Massachusetts, Sch Med, Canc Ctr Excellence, Worcester, MA USA

[11] Hop Haut Leveque, Giround, France

[12] Hop St Antoine, Paris, France

[13] Hosp Univ Marques de Valdecilla, Santander, Spain

[14] McGill Univ, Royal Inst, Montreal, PQ, Canada

[15] Azienda Osped Univ San Martino, Genoa, Italy

[16] Georgetown Univ, Dept Med & Oncol, Lombardi Comprehens Canc Ctr, Washington, DC USA

[17] Georgetown Univ, Innovat Ctr Biomed Informat, Lombardi Comprehens Canc Ctr, Washington, DC USA

[18] Celgene Corp, Summit, NJ USA

[19] Karmanos Canc Ctr, Detroit, MI USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期

关键词：

D O I：

10.1200/JCO.2017.35.4_suppl.358

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

358

引用

页数：1

共 50 条

[21] A pilot phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC)
MacKenzie, Shawn
Zeh, Herbert
McCahill, Laurence E.
Sielaff, Timothy D.
Bahary, Nathan
Gribbin, Thomas Edward
Seng, John E.
Leach, Joseph W.
Harmon, Jocelyn
Demeure, Michael J.
Von Hoff, Daniel D.
Moser, A. Jim
Ramanathan, Ramesh K.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[22] Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)
Chiorean, E. G.
Cheung, W. Y.
Giordano, G.
Kim, G.
Al-Batran, S-E.
ANNALS OF ONCOLOGY, 2018, 29 : 245 - 246
[23] Gemcitabine (G) plus nab-paclitaxel (nab-P) versus G in patients (pts) with advanced pancreatic cancer (PDAC) after FOLFIRINOX: A single center, retrospective review.
Chan, Edmond Mankee
Hong, Theodore S.
Clark, Jeffrey William
Blaszkowsky, Lawrence Scott
Allen, Jill N.
Zhu, Andrew
Goyal, Lipika
Murphy, Janet E.
Kwak, Eunice L.
Wo, Jennifer Y.
Ryan, David P.
Faris, Jason Edward
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[24] Phase 1 study of nivolumab (nivo) plus nab-paclitaxel (nab-P) ± gemcitabine (G) in pancreatic cancer (PC): safety evaluation of patients treated with nivo plus nab-P in arm A
Hochster, Howard S.
Wainberg, Zev A.
Gutierrez, Martin
Waterhouse, David
Chiorean, E. Gabriela
George, Ben
Ko, Amy
Manax, Victoria
Stergiopoulos, Sotirios
O'Dwyer, Peter
CANCER RESEARCH, 2016, 76
[25] FOLFOX and nab-paclitaxel (nab-P) for advanced pancreatic cancer: A phase I study
Safran, Howard
Charpentier, Kevin
Perez, Kimberly
Mantripragada, Kalyan
Austin, Trevor Clark
Nadeem, Omar
Lombardo, Alise
Houlihan, Lindsay
Fontes-Borts, Lucia
Kolberg, Irene
Mitchell, Kristen
Rosati, Kayla
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[26] Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Park, J. Oh
Li, C-P.
Chang, H-M.
Shan, Y. S.
Bendell, J.
Garlipp, B.
Hatoum, H.
Laquente Saez, B.
Salminen, T.
Oettle, H.
Kocsis, J.
Lopez, R.
Dowden, S.
Karthaus, M.
Lu, B.
McGovern, D.
Banerjee, S.
Tempero, M.
Oh, D-Y.
ANNALS OF ONCOLOGY, 2020, 31 : S1313 - S1313
[27] randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
Tempero, Margaret A.
Reni, Michele
Riess, Hanno
Pelzer, Uwe
O'Reilly, Eileen Mary
Winter, Jordan Michael
Oh, Do-Youn
Li, Chung-Pin
Tortora, Giampaolo
Chang, Heung-Moon
Lopez, Charles D.
Tabernero, Josep
Van Cutsem, Eric
Philip, Philip Agop
Goldstein, David
Berlin, Jordan
Ferrara, Stefano
Li, Mingyu
Lu, Brian D.
Biankin, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[28] Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recurrence patterns
Sahai, Vaibhav
Tabernero, Josep
Van Cutsem, Eric
Reni, Michele
Tempero, Margaret A.
O'Reilly, Eileen Mary
Berlin, Jordan
Riess, Hanno
Goldstein, David
Li, Mingyu
Lu, Brian
Ferrara, Stefano
Philip, Philip Agop
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[29] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
Tsujimoto, Akiko
Sudo, Kentaro
Nakamura, Kazuyoshi
Kita, Emiri
Hara, Ryusuke
Takayama, Wataru
Ishii, Hiroshi
Yamaguchi, Taketo
SCIENTIFIC REPORTS, 2019, 9 (1)
[30] Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Von Hoff, Daniel D.
Ramanathan, Ramesh K.
Borad, Mitesh J.
Laheru, Daniel A.
Smith, Lon S.
Wood, Tina E.
Korn, Ronald L.
Desai, Neil
Trieu, Vuong
Iglesias, Jose L.
Zhang, Hui
Soon-Shiong, Patrick
Shi, Tao
Rajeshkumar, N. V.
Maitra, Anirban
Hidalgo, Manuel
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (34) : 4548 - 4554

← 1 2 3 4 5 →